Medicare prescription drug benefit; Drug rebates for Medicare Part D; Part D benefit structure; Payment policies for Medicare Part B Prescription drugs; Independent Payment Advisory Board (IPAB), repeal of Part D Non-interference Provision; CCMI Medicare Part B Demonstration.
H.R. 34, 21st Century Cures ACT; Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Senate Finance Committee Chronic Disease Initiative; Implementation of Precision Medicine Initiative; White House Cancer Moonshot; Legislation affecting the ESRD program.
Tax issues affecting the pharmaceutical industry, tax reform issues.
Duration: January 1, 2008
to
January 1, 2017
General Issues: Medicare/Medicaid , Health Issues , Taxation/Internal Revenue Code , Veterans , Foreign Relations
Spending: about $2,050,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2008: U.S. Senate, House of Representatives, Office of the Vice President of the United States, Vice President of the U.S., U.S. Senate,, Commerce - Dept of (DOC), State - Dept of (DOS), White House Office
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Karina Lynch Staff, Senate Special Committee on Aging
Susan Hirschmann COS, Rep.Van Hilleary and Majority Whip
COS, Rep.Van Hilleary & Majority Whip
Cheryl Jaeger Shared Employ Ofc of the Speaker & Ofc VA 7
Sr. Policy Adv, Majority Leader, Rep Cantor
Sr. Policy Adv, Republican Whip, Rep. Cantor
Sr. Policy Adv, Majority Whip Rep Blunt
Prof Staff House Committee on E&C
Sr. LA To Rep. Christopher Cox
Sr. LA to Rep. Christopher Cox
Christopher Hatcher Sch. C, Treasury. ; LD, Rep. Scott McInnis
Staff Asst.; Special Asst,; & Leg. Manger, Treasury.
Jenny DiJames LA and LD, Rep. Bud Cramer
Tony Roda Leadership Staff, House Whip Gingrich
Michael Beer LA, Rep. Dave Hobson
Eric Stewart COS and Deputy Asst. Sec., Dept. of Commerce
Joel Oswald Prof. Staff, Senate Banking; LA, Sen. Enzi
Prof.Staff,, Senate Banking Comte; LA,Sen.Enzi.
Joyce Rogers Rep. Steny Hoyer and Rep. Corrine Brown
Rebecca Anderson White House Office of Legislative Affairs
Karina Lynch continued Staff, Senate Committee on Government Affairs
Christopher Hatcher continued LD, Rep. Scott McInnis
George Olsen n/a
Erin Book Mullen n/a
J. Steven Hart n/a
Matthew Hoekstra n/a
Melinda Maxfield n/a
Anthony Roda n/a
Erin Mullen n/a
Tess Illos n/a
Erin Book n/a
George Olson n/a
Matt Hoekstra n/a
Goerge Olsen n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2017
Williams and Jensen, PLLC terminated an engagement in which they represented AstraZeneca Pharmaceuticals LP (formerly AstraZeneca Pharmaceuticals Group) on April 19, 2017.
Original Filing: 300868936.xml
4th Quarter, 2016
In Q4, Williams and Jensen, PLLC lobbied for AstraZeneca Pharmaceuticals LP (formerly AstraZeneca Pharmaceuticals Group) , earning $50,000. The report was filed on Jan. 12, 2017.
Original Filing: 300845283.xml
Lobbying Issues
Medicare prescription drug benefit; Drug rebates for Medicare Part D; Part D benefit structure; Payment policies for Medicare Part B Prescription drugs; Independent Payment Advisory Board (IPAB), repeal of Part D Non-interference Provision; CCMI Medicare Part B Demonstration.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 34, 21st Century Cures ACT; Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Senate Finance Committee Chronic Disease Initiative; Implementation of Precision Medicine Initiative; White House Cancer Moonshot; Legislation affecting the ESRD program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues affecting the pharmaceutical industry, tax reform issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2016
In Q3, Williams and Jensen, PLLC lobbied for AstraZeneca Pharmaceuticals LP (formerly AstraZeneca Pharmaceuticals Group) , earning $50,000. The report was filed on Oct. 12, 2016.
Original Filing: 300826620.xml
Lobbying Issues
Medicare prescription drug benefit; Drug rebates for Medicare Part D; Part D benefit structure; Payment policies for Medicare Part B Prescription drugs; Independent Payment Advisory Board (IPAB), repeal of Part D Non-interference Provision; CCMI Medicare Part B Demonstration.
Agencies Lobbied
U.S. Senate
Lobbying Issues
21st Century Cures Initiative (House Energy and Commerce Committee) and Innovations for Healthier Americans (Senate Health, Education, Labor and Pensions Committee); possible drug provisions in FY 2017 appropriations bills; Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Senate Finance Committee Chronic Disease Initiative; Implementation of Precision Medicine Initiative; White House Cancer Moonshot; Legislation affecting the ESRD program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues affecting the pharmaceutical industry, tax reform issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2016
In Q2, Williams and Jensen, PLLC lobbied for AstraZeneca Pharmaceuticals LP (formerly AstraZeneca Pharmaceuticals Group) , earning $50,000. The report was filed on July 12, 2016.
Original Filing: 300808573.xml
Lobbying Issues
Medicare prescription drug benefit; Drug rebates for Medicare Part D; Part D benefit structure; Payment policies for Medicare Part B Prescription drugs; Independent Payment Advisory Board (IPAB).
Agencies Lobbied
U.S. Senate
Lobbying Issues
21st Century Cures Initiative (House Energy and Commerce Committee) and Innovations for Healthier Americans (Senate Health, Education, Labor and Pensions Committee); possible drug provisions in FY 2017 appropriations bills; Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Senate Finance Committee Chronic Disease Initiative; Implementation of Precision Medicine Initiative; White House Cancer Moonshot; Legislation affecting the ESRD program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues affecting the pharmaceutical industry, tax reform issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2016
Williams and Jensen, PLLC amended a lobbying report for representation of AstraZeneca Pharmaceuticals LP (formerly AstraZeneca Pharmaceuticals Group) in Q12016 on April 15, 2016.
Original Filing: 300792275.xml
Lobbying Issues
Medicare prescription drug benefit; Drug rebates for Medicare Part D; Part D benefit structure; Independent Payment Advisory Board (IPAB).
Agencies Lobbied
U.S. Senate
Lobbying Issues
21st Century Cures Initiative (House Energy and Commerce Committee) and Innovations for Healthier Americans (Senate Health, Education, Labor and Pensions Committee); possible drug provisions in Continuing Resolution and Consolidated Appropriations Act, 2016; Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Senate Finance Committee chronic disease initiative; Implementation of Precision Medicine Initiative.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Williams and Jensen, PLLC lobbied for AstraZeneca Pharmaceuticals LP (formerly AstraZeneca Pharmaceuticals Group) , earning $50,000. The report was filed on April 14, 2016.
Original Filing: 300791366.xml
Lobbying Issues
Medicare prescription drug benefit; Drug rebates for Medicare Part D; Part D benefit structure; Independent Payment Advisory Board (IPAB; repeal of Part D Non-interference provision.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Innovations for Healthier Americans (Senate Health, Education, Labor and Pensions Committee); Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Senate Finance Committee chronic disease initiative; Implementation of Precision Medicine Initiative; White House Cancer Moonshot.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues affecting the pharmaceutical industry, tax reform issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2015
In Q4, Williams and Jensen, PLLC lobbied for AstraZeneca Pharmaceuticals LP (formerly AstraZeneca Pharmaceuticals Group) , earning $50,000. The report was filed on Jan. 12, 2016.
Original Filing: 300770603.xml
Lobbying Issues
Medicare prescription drug benefit; Drug rebates for Medicare Part D; Part D benefit structure; Independent Payment Advisory Board (IPAB).
Agencies Lobbied
U.S. Senate
Lobbying Issues
21st Century Cures Initiative (House Energy and Commerce Committee) and Innovations for Healthier Americans (Senate Health, Education, Labor and Pensions Committee); possible drug provisions in Continuing Resolution and Consolidated Appropriations Act, 2016; Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Senate Finance Committee chronic disease initiative; Implementation of Precision Medicine Initiative.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues affecting the pharmaceutical industry, tax reform issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2015
In Q3, Williams and Jensen, PLLC lobbied for AstraZeneca Pharmaceuticals LP (formerly AstraZeneca Pharmaceuticals Group) , earning $50,000. The report was filed on Oct. 16, 2015.
Original Filing: 300754364.xml
Lobbying Issues
Medicare prescription drug benefit; Drug rebates for Medicare Part D; Part D benefit structure; Independent Payment Advisory Board (IPAB).
Agencies Lobbied
U.S. Senate
Lobbying Issues
21st Century Cures Initiative (House Energy and Commerece Committee) and Innovations for Healthier Americans (Senate Health, Education, Labor and Pensions Committee); possible drug provisions in Continuing Resolution; Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Senate Finance Committee chronic disease initiative.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues affecting the pharmaceutical industry, tax reform issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2015
In Q2, Williams and Jensen, PLLC lobbied for AstraZeneca Pharmaceuticals LP (formerly AstraZeneca Pharmaceuticals Group) , earning $50,000. The report was filed on July 16, 2015.
Original Filing: 300735992.xml
Lobbying Issues
Medicare prescription drug benefit; Drug rebates for Medicare Part D; Part D benefit structure; Independent Payment Advisory Board (IPAB).
Agencies Lobbied
U.S. Senate
Lobbying Issues
21st Century Cures Initiative (House Energy and Commerece Committee) and Innovations for Healthier Americans (Senate Health, Education, Labor and Pensions Committee); potential pharmaceutical provisions in House Budget Resolution (H. Con. Res. 27) and Senate Budget Resolution (S. Con. Res. 11); Possible drug provisions in H.R. 2, the Medicare Access and CHIP Reauthorization Act; Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Prescription drug advertising; Federal preemption for prescription drugs; Drug shortages.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues affecting the pharmaceutical industry, tax reform issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2015
In Q1, Williams and Jensen, PLLC lobbied for AstraZeneca Pharmaceuticals LP (formerly AstraZeneca Pharmaceuticals Group) , earning $50,000. The report was filed on April 14, 2015.
Original Filing: 300715030.xml
Lobbying Issues
Medicare prescription drug benefit; Drug rebates for Medicare Part D; Part D benefit structure; Independent Payment Advisory Board (IPAB).
Agencies Lobbied
U.S. Senate
Lobbying Issues
21st Century Cures Initiative (House Energy and Commerece Committee) and Innovations for Healthier Americans (Senate Health, Education, Labor and Pensions Committee); potential pharmaceutical provisions in House Budget Resolution (H. Con. Res. 27) and Senate Budget Resolution (S. Con. Res. 11); Possible drug provisions in H.R. 2, the Medicare Access and CHIP Reauthorization Act; Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Prescription drug advertising; Federal preemption for prescription drugs; Drug shortages.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues affecting the pharmaceutical industry, tax reform issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2014
In Q4, Williams & Jensen, PLLC. lobbied for AstraZeneca Pharmaceuticals LP (formerly AstraZeneca Pharmaceuticals Group) , earning $50,000. The report was filed on Jan. 15, 2015.
Original Filing: 300696214.xml
Lobbying Issues
Medicare prescription drug benefit. Drug rebates for Medicare Part D. Part D benefit structure. Indpendent Payment Advisory Board (IPAB).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act; Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Prescription drug advertising; Federal preemption for prescription drugs; drug shortages; Work on 21st Century Cures Initiative
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry, tax reform issues.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Pharmaceutical sourcing from non-Trade Agreement Act countries.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2014
In Q3, Williams & Jensen, PLLC. lobbied for AstraZeneca Pharmaceuticals LP (formerly AstraZeneca Pharmaceuticals Group) , earning $50,000. The report was filed on Oct. 17, 2014.
Original Filing: 300680093.xml
Lobbying Issues
Medicare prescription drug benefit. Drug rebates for Medicare Part D. Part D benefit structure. Indpendent Payment Advisory Board (IPAB).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act; Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Prescription drug advertising; Federal preemption for prescription drugs; drug shortages; Work on 21st Century Cures Initiative
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry, tax reform issues.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Pharmaceutical sourcing from non-Trade Agreement Act countries.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
Commerce - Dept of (DOC)
2nd Quarter, 2014
In Q2, Williams & Jensen, PLLC. lobbied for AstraZeneca Pharmaceuticals LP (formerly AstraZeneca Pharmaceuticals Group) , earning $80,000. The report was filed on July 18, 2014.
Original Filing: 300661967.xml
Lobbying Issues
Medicare prescription drug benefit. Drug rebates for Medicare Part D. Part D benefit structure. Indpendent Payment Advisory Board (IPAB).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act. Drug safety and drug counterfeiting. (track and trace)
Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Prescription drug advertising; Federal preemption for prescription drugs; drug shortages.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry, tax reform issues.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Pharmaceutical sourcing from non-Trade Agreement Act countries.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
Commerce - Dept of (DOC)
2nd Quarter, 2014
Williams & Jensen, PLLC. amended a lobbying report for representation of AstraZeneca Pharmaceuticals LP (formerly AstraZeneca Pharmaceuticals Group) in Q22014 on July 18, 2014.
Original Filing: 300661976.xml
Lobbying Issues
Medicare prescription drug benefit. Drug rebates for Medicare Part D. Part D benefit structure. Indpendent Payment Advisory Board (IPAB).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act. Drug safety and drug counterfeiting.
Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Prescription drug advertising; Federal preemption for prescription drugs; drug shortages.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry, tax reform issues.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Pharmaceutical sourcing from non-Trade Agreement Act countries.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
Commerce - Dept of (DOC)
1st Quarter, 2014
In Q1, Williams & Jensen, PLLC. lobbied for AstraZeneca Pharmaceuticals LP (formerly AstraZeneca Pharmaceuticals Group) , earning $80,000. The report was filed on April 17, 2014.
Original Filing: 300638498.xml
Lobbying Issues
Medicare prescription drug benefit. Drug rebates for Medicare Part D. Part D benefit structure. Indpendent Payment Advisory Board (IPAB).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act. Drug safety and drug counterfeiting. (track and trace)
Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Prescription drug advertising; Federal preemption for prescription drugs; drug shortages.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry, tax reform issues.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Pharmaceutical sourcing from non-Trade Agreement Act countries.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
Commerce - Dept of (DOC)
4th Quarter, 2013
In Q4, Williams & Jensen, PLLC. lobbied for AstraZeneca Pharmaceuticals LP (formerly AstraZeneca Pharmaceuticals Group) , earning $80,000. The report was filed on Jan. 16, 2014.
Original Filing: 300616526.xml
Lobbying Issues
Medicare prescription drug benefit. Drug rebates for Medicare Part D. Part D benefit structure. Indpendent Payment Advisory Board (IPAB). House and Senate action on H.J. Res. 59 and possible drug industry issues.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act. Drug safety and drug counterfeiting. (track and trace)
Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Prescription drug advertising; Federal preemption for prescription drugs; drug shortages.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry, tax reform issues.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Pharmaceutical sourcing from non-Trade Agreement Act countries.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
Commerce - Dept of (DOC)
3rd Quarter, 2013
In Q3, Williams & Jensen, PLLC. lobbied for AstraZeneca Pharmaceuticals LP (formerly AstraZeneca Pharmaceuticals Group) , earning $80,000. The report was filed on Oct. 18, 2013.
Original Filing: 300598800.xml
Lobbying Issues
Medicare prescription drug benefit; drug rebates for Medicare Part D. Part D benefit structures. Indpendent Payment Advisory Board (IPAB). House and Senate Budget resolutions.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act. Drug safety and drug counterfeiting. (track and trace)
Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Prescription drug advertising; Federal preemption for prescription drugs; drug shortages.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry, tax reform issues.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Pharmaceutical sourcing from non-Trade Agreement Act countries.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
Commerce - Dept of (DOC)
2nd Quarter, 2013
In Q2, Williams & Jensen, PLLC. lobbied for AstraZeneca Pharmaceuticals LP (formerly AstraZeneca Pharmaceuticals Group) , earning $80,000. The report was filed on July 19, 2013.
Original Filing: 300578431.xml
Lobbying Issues
Medicare prescription drug benefit; drug rebates for Medicare Part D. Indpendent Payment Advisory Board (IPAB). House and Senate Budget resolutions.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act. Drug safety and drug counterfeiting. (track and trace)
Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Prescription drug advertising; Federal preemption for prescription drugs; drug shortages.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry, tax reform issues.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Pharmaceutical sourcing from non-Trade Agreement Act countries.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
Commerce - Dept of (DOC)
1st Quarter, 2013
In Q1, Williams & Jensen, PLLC. lobbied for AstraZeneca Pharmaceuticals LP (formerly AstraZeneca Pharmaceuticals Group) , earning $80,000. The report was filed on April 22, 2013.
Original Filing: 300559619.xml
Lobbying Issues
Medicare prescription drug benefit; drug rebates for Medicare Part D. Indpendent Payment Advisory Board (IPAB). House and Senate Budget resolutions; Continuing Resolution Appropriations for FY 2013 (H.R. 933)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act. Drug safety and drug counterfeiting. (track and trace)
Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Prescription drug advertising; Federal preemption for prescription drugs; drug shortages.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry, tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Pharmaceutical sourcing from non-Trade Agreement Act countries.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
In Q4, Williams & Jensen, PLLC. lobbied for AstraZeneca Pharmaceuticals LP (formerly AstraZeneca Pharmaceuticals Group) , earning $50,000. The report was filed on Jan. 18, 2013.
Original Filing: 300533398.xml
Lobbying Issues
Medicare prescription drug benefit; drug rebates for Medicare Part D. Indpendent Payment Advisory Board (IPAB). American Taxpayer Relief Act of 2012.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act. Drug safety and drug counterfeiting.
Drug importation; 340B Program; Authorized generics; Drug company settlements including S. 27, Preserve Access to Affordable Generics Act; Prescription drug advertising; Federal preemption for prescription drugs; drug shortages; and Non Trade Agreements Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
American Taxpayer Relief Act of 2012. Pharmaceutical sourcing from non-Trade Agreement Act countries.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, Williams & Jensen, PLLC. lobbied for AstraZeneca Pharmaceuticals LP (formerly AstraZeneca Pharmaceuticals Group) , earning $50,000. The report was filed on Oct. 19, 2012.
Original Filing: 300512472.xml
Lobbying Issues
Medicare prescription drug benefit; drug rebates for Medicare Part D. Indpendent Payment Advisory Board (IPAB)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act. Drug safety and drug counterfeiting.
Drug importation; 340B Program; Authorized generics; Drug company settlements including S. 27, Preserve Access to Affordable Generics Act; Prescription drug advertising; Federal preemption for prescription drugs; drug shortages.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2012
In Q2, Williams & Jensen, PLLC. lobbied for AstraZeneca Pharmaceuticals LP (formerly AstraZeneca Pharmaceuticals Group) , earning $50,000. The report was filed on July 19, 2012.
Original Filing: 300490000.xml
Lobbying Issues
Medicare prescription drug benefit; drug rebates for Medicare Part D. Indpendent Payment Advisory Board (IPAB)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act. Drug safety and drug counterfeiting.
Drug importation; 340B Program; Authorized generics; Drug company settlements including S. 27, Preserve Access to Affordable Generics Act; Prescription drug advertising; Federal preemption for prescription drugs; drug shortages (FDA Safety and Innovation Act (S. 3187)) and Reauthorization of the Prescription Drug User Fee Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2012
In Q1, Williams & Jensen, PLLC. lobbied for AstraZeneca Pharmaceuticals LP (formerly AstraZeneca Pharmaceuticals Group) , earning $50,000. The report was filed on April 20, 2012.
Original Filing: 300471937.xml
Lobbying Issues
Medicare prescription drug benefit. Drug rebates for Medicare Part D. Indpendent Payment Advisory Board (IPAB)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act. Drug safety and drug counterfeiting.
Drug importation; 340B Program; Authorized generics; Drug company settlements including S. 27, Preserve Access to Affordable Generics Act; Prescription drug advertising; Federal preemption for prescription drugs; drug shortages
and Reauthorization of the Prescription Drug User Fee Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2011
In Q4, Williams & Jensen, PLLC. lobbied for AstraZeneca Pharmaceuticals LP (formerly AstraZeneca Pharmaceuticals Group) , earning $50,000. The report was filed on Jan. 20, 2012.
Original Filing: 300448967.xml
Lobbying Issues
Medicare prescription drug benefit. Drug rebates for Medicare Part D.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act. Drug safety and drug counterfeiting.
Drug importation; 340B Program; Authorized generics; Drug company settlements including S. 27, Preserve Access to Affordable Generics Act; Stem cell research Prescription drug advertising; Federal preemption for prescription drugs;
Legislation concerning civil litigation; and Reauthorization of the Prescription Drug User Fee Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2011
In Q3, Williams & Jensen, PLLC. lobbied for ASTRAZENECA PHARMACEUTICALS GROUP , earning $50,000. The report was filed on Oct. 20, 2011.
Original Filing: 300425881.xml
Lobbying Issues
Medicare prescription drug benefit. Drug rebates for Medicare Part D.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act. Drug safety and drug counterfeiting.
Drug importation; 340B Program; Authorized generics; Drug company settlements including S. 27, Preserve Access to Affordable Generics Act; Stem cell research Prescription drug advertising; Federal preemption for prescription drugs;
Legislation concerning civil litigation; and Reauthorization of the Prescription Drug User Fee Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2011
In Q2, Williams & Jensen, PLLC. lobbied for ASTRAZENECA PHARMACEUTICALS GROUP , earning $50,000. The report was filed on July 20, 2011.
Original Filing: 300405928.xml
Lobbying Issues
Medicare prescription drug benefit. Drug rebates for Medicare Part D.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act. Drug safety and drug counterfeiting.
Drug importation; 340B Program; Authorized generics; Drug company settlements including S. 27, Preserve Access to Affordable Generics Act; Stem cell research Prescription drug advertising; Federal preemption for prescription drugs;
Legislation concerning civil litigation; and Reauthorization of the Prescription Drug User Fee Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2011
In Q1, Williams & Jensen, PLLC. lobbied for ASTRAZENECA PHARMACEUTICALS GROUP , earning $50,000. The report was filed on April 20, 2011.
Original Filing: 300375051.xml
Lobbying Issues
Medicare prescription drug benefit.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act. Drug safety and drug counterfeiting.
Drug importation; 340B Program; Authorized generics; Drug company settlements including S. 27, Preserve Access to Affordable Generics Act; Stem cell research Prescription drug advertising; Federal preemption for prescription drugs;
Legislation concerning civil litigation; and Reauthorization of the Prescription Drug User Fee Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2010
In Q4, Williams & Jensen, PLLC. lobbied for ASTRAZENECA PHARMACEUTICALS GROUP , earning $50,000. The report was filed on Jan. 20, 2011.
Original Filing: 300350581.xml
Lobbying Issues
Medicare prescription drug benefit
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act;
Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009;
340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act;
Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act;
Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill;
Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009;
Prescription drug advertising;
Federal preemption for prescription drugs; and
Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2010
In Q3, Williams & Jensen, PLLC. lobbied for ASTRAZENECA PHARMACEUTICALS GROUP , earning $50,000. The report was filed on Oct. 20, 2010.
Original Filing: 300323337.xml
Lobbying Issues
Medicare prescription drug benefit
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act;
Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009;
340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act;
Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act;
Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill;
Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009;
Prescription drug advertising;
Federal preemption for prescription drugs; and
Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2010
In Q2, Williams & Jensen, PLLC. lobbied for ASTRAZENECA PHARMACEUTICALS GROUP , earning $50,000. The report was filed on July 15, 2010.
Original Filing: 300286949.xml
Lobbying Issues
Medicare prescription drug benefit
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act;
Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009;
340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act;
Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act;
Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act;
Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009;
Prescription drug advertising;
Federal preemption for prescription drugs; and
Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2010
In Q1, Williams & Jensen, PLLC. lobbied for ASTRAZENECA PHARMACEUTICALS GROUP , earning $50,000. The report was filed on April 20, 2010.
Original Filing: 300270077.xml
Lobbying Issues
Medicaid drug rebates including S. 547/H.R. 904, Drug Rebate Equalization Act of 2009; H.R. 1725, Voluntary State Discount Prescription Drug Plan Act of 2009; and
H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010.
Medicare drug price negotiation, payment, and coverage including S. 330/H.R. 684, Medicare Prescription Drug Savings and Choice Act of 2009; S. 266, Medicare Prescription Drug Gap Reduction Act of 2009; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act;
Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; H.R. 3590, Patient Protection and Affordable Care Act.
Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010.
Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010.
Comparative effectiveness including S. 1213, Patient-Centered Outcomes Research Act of 2009; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010.
Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act;
Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010.
Health care reform including H.R. 3200, America's Affordable Health Choices Act; S. , Affordable Health Choices Act; and S. , America's Healthy Future Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010.
Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009;
Prescription drug advertising;
Federal preemption for prescription drugs; and
Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2009
In Q4, Williams & Jensen, PLLC. lobbied for ASTRAZENECA PHARMACEUTICALS GROUP , earning $50,000. The report was filed on Jan. 20, 2010.
Original Filing: 300242051.xml
Lobbying Issues
Medicaid drug rebates including S. 547/H.R. 904, Drug Rebate Equalization Act of 2009; H.R. 1725, Voluntary State Discount Prescription Drug Plan Act of 2009; and
Medicare drug price negotiation, payment, and coverage including S. 330/H.R. 684, Medicare Prescription Drug Savings and Choice Act of 2009; S. 266, Medicare Prescription Drug Gap Reduction Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act;
Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009;
Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act;
Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009;
Comparative effectiveness including H.R. 1, the American Recovery and Reinvestment Act; S. 1213, Patient-Centered Outcomes Research Act of 2009;
Health information technology including H.R. 1, the American Recovery and Reinvestment Act;
Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act;
Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act;
Health care reform including H.R. 3200, America's Affordable Health Choices Act; S. , Affordable Health Choices Act; and S. , America's Healthy Future Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act;
Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009;
Prescription drug advertising;
Federal preemption for prescription drugs; and
Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2009
In Q3, Williams & Jensen, PLLC. lobbied for ASTRAZENECA PHARMACEUTICALS GROUP , earning $50,000. The report was filed on Oct. 20, 2009.
Original Filing: 300219265.xml
Lobbying Issues
Medicaid drug rebates including S. 547/H.R. 904, Drug Rebate Equalization Act of 2009; H.R. 1725, Voluntary State Discount Prescription Drug Plan Act of 2009; and
Medicare drug price negotiation, payment, and coverage including S. 330/H.R. 684, Medicare Prescription Drug Savings and Choice Act of 2009; S. 266, Medicare Prescription Drug Gap Reduction Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act;
Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009;
Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act;
Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009;
Comparative effectiveness including H.R. 1, the American Recovery and Reinvestment Act; S. 1213, Patient-Centered Outcomes Research Act of 2009;
Health information technology including H.R. 1, the American Recovery and Reinvestment Act;
Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act;
Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act;
Health care reform including H.R. 3200, America's Affordable Health Choices Act; S.___, Affordable Health Choices Act; and S.___, America's Healthy Future Act;
Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009;
Prescription drug advertising;
Federal preemption for prescription drugs; and
Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2009
In Q2, Williams & Jensen, PLLC. lobbied for ASTRAZENECA PHARMACEUTICALS GROUP , earning $50,000. The report was filed on July 20, 2009.
Original Filing: 300187475.xml
Lobbying Issues
Medicaid drug rebates including S. 547/H.R. 904, Drug Rebate Equalization Act of 2009; H.R. 1725, Voluntary State Discount Prescription Drug Plan Act of 2009; and
Medicare drug price negotiation, payment, and coverage including S. 330/H.R. 684, Medicare Prescription Drug Savings and Choice Act of 2009; S. 266, Medicare Prescription Drug Gap Reduction Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act;
Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009;
Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act;
Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009;
Comparative effectiveness including H.R. 1, the American Recovery and Reinvestment Act; S. 1213, Patient-Centered Outcomes Research Act of 2009;
Health information technology including H.R. 1, the American Recovery and Reinvestment Act;
Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act;
Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act;
Health care reform including the Affordable Health Choices Act;
Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009;
Prescription drug advertising;
Federal preemption for prescription drugs; and
Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2009
In Q1, Williams & Jensen, PLLC. lobbied for ASTRAZENECA PHARMACEUTICALS GROUP , earning $100,000. The report was filed on April 20, 2009.
Original Filing: 300160533.xml
Lobbying Issues
Medicaid drug rebates including S. 547/H.R. 904, Drug Rebate Equalization Act of 2009; H.R. 1725, Voluntary State Discount Prescription Drug Plan Act of 2009; and
Medicare drug price negotiation, payment, and coverage including S. 330/H.R. 684, Medicare Prescription Drug Savings and Choice Act of 2009; S. 266, Medicare Prescription Drug Gap Reduction Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009
Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act;
Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009;
Comparative effectiveness including H.R. 1, the American Recovery and Reinvestment Act;
Health information technology including H.R. 1, the American Recovery and Reinvestment Act;
Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act;
Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act;
Health care reform;
Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009;
Prescription drug advertising;
Federal preemption for prescription drugs; and
Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2008
In Q4, Williams & Jensen, PLLC. lobbied for ASTRAZENECA PHARMACEUTICALS GROUP , earning $60,000. The report was filed on Jan. 21, 2009.
Original Filing: 300130269.xml
Lobbying Issues
Medicare drug benefit; Medicaid drug rebate; Drug price negotiation; Medicare Improvements for Patients and Providers Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Drug importation and counterfeiting; drug safety/clinical trials; follow-on biologics; drug advertising; comparative effectiveness; mental health parity; physician payment disclosure legislation; and preemption.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the drug industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2008
In Q3, Williams & Jensen, PLLC. lobbied for ASTRAZENECA PHARMACEUTICALS GROUP , earning $50,000. The report was filed on Oct. 20, 2008.
Original Filing: 300104582.xml
Lobbying Issues
Medicare drug benefit; Medicaid drug rebate; drug price negotiation; medicare Improvements for Patients and Providers Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Drug importation and counterfeiting; drug safety/clinical trials; follow-on biolgoics; drug advertising; comparative effectiveness; mental health parity; Physician payment disclosure legislation.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the drug industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2008
In Q2, Williams & Jensen, PLLC. lobbied for ASTRAZENECA PHARMACEUTICALS GROUP , earning $60,000. The report was filed on July 17, 2008.
Original Filing: 300069670.xml
Lobbying Issues
Medicare drug benefit; Medicaid drug rebate; drug price negotiation.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Drug importation and counterfeiting; drug safety/clinical trials; follow-on biolgoics; drug advertising; comparative effectiveness; mental health parity; drug payment disclosure legislation; S. 2029.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the drug industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2008
In Q1, Williams & Jensen, PLLC. lobbied for ASTRAZENECA PHARMACEUTICALS GROUP , earning $50,000. The report was filed on April 21, 2008.
Original Filing: 300049600.xml
Lobbying Issues
Medicare drug benefit; Medicaid drug rebate; drug price negotiation.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Drug importation and counterfeiting; drug safety/clinical trials; follow-on biolgoics; drug advertising; comparative effectiveness; mental health parity; drug payment disclosure legislation; S. 2029.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the drug industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...